Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 930Neoplasms 708Prostatic Neoplasms 490Lung Neoplasms 398Carcinoma, Non-Small-Cell Lung 359Colorectal Neoplasms 357Leukemia, Myeloid, Acute 290Pancreatic Neoplasms 238Brain Neoplasms 227Neoplasm Metastasis 221Multiple Myeloma 214Carcinoma, Hepatocellular 199Head and Neck Neoplasms 182Glioblastoma 181Precursor Cell Lymphoblastic Leukemia-Lymphoma 177Melanoma 173Ovarian Neoplasms 168Squamous Cell Carcinoma of Head and Neck 160Uterine Cervical Neoplasms 144Rectal Neoplasms 144Recurrence 142Hematologic Neoplasms 134Sarcoma 133Triple Negative Breast Neoplasms 127Stomach Neoplasms 127Glioma 126Carcinoma, Renal Cell 123Colonic Neoplasms 113Myelodysplastic Syndromes 112Urinary Bladder Neoplasms 109

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × 90 days × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡